Edgar Filing: AERIE PHARMACEUTICALS INC - Form 4

AERIE PHAI Form 4 February 27, 2	RMACEUTICAL 2015	S INC									
FORM Check this if no longe subject to Section 16 Form 4 or Form 5 obligation may contin <i>See</i> Instruct 1(b).	4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0287 box STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Expires: January 31, 2005 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 0.5										
(Print or Type R 1. Name and Ac RUBINO RI	ol IE PHARMA	er Name and Ticker or Trading E PHARMACEUTICALS INC				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
	(First) (Mi EUTICALS, INC. EET, SUITE 1500	iddle) 3. Data (Month 02/25	[AERI] 3. Date of Earliest Transaction (Month/Day/Year) 02/25/2015				below)	X_Officer (give title Other (specify			
IRVINE, CA (City)	Amendment, Date Original Month/Day/Year)				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person quired, Disposed of, or Beneficially Owned						
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		3. if Transaction Code ar) (Instr. 8)	4. Securi onAcquirec Disposec (Instr. 3, Amount	ties l (A) c l of (D	or))	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	•		
Common Stock	02/25/2015		А	9,063 (1)	А	\$0	390,097	D			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	Derivative Conversion (Month/Day/Year) Execut ecurity or Exercise any		Execution Date, if	Code	5. Number of tiorDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)8(
				Code V	(A) (I		Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 28.03	02/25/2015		А	54,375		(2)	02/25/2025	Common Stock	54,375
Reporting Owners										
Re	enorting Own	Relationships								
Reporting Owner Name / Address			Director	10% Owner Officer				Other		
RUBINO RICHARD J C/O AERIE PHARMACEUTICALS, INC., 2030 MAIN STREET, SUITE 1500 IRVINE, CA 92614				Chief Financial Officer						
Signa	tures									

Edgar Filing: AERIE PHARMACEUTICALS INC - Form 4

Signatures

/s/ Richard J. 02/27/2015 Rubino **Signature of Date Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). **
- These shares of Common Stock are scheduled to vest, subject to the reporting person's continued employment with the issuer through the (1) applicable vesting date, in four equal annual installments on the anniversary of February 25, 2015.
- This option is scheduled to vest, subject to the reporting person's continued employment with the issuer through the applicable vesting (2)date, ratably on each of the 48 monthly anniversaries of February 25, 2015.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.